BEAM
Beam Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$24.95
+1.13%Next report
Analyst consensus
- Next report date
- Nov 3, 2026
- EPS estimate
- -$1.16
- Revenue estimate
- $8.8M
Latest reported
- Last report date
- Aug 4, 2026
- EPS actual
- -$1.18
- EPS estimate
- -$1.11
- Revenue actual
- $490.0K
- Revenue estimate
- $16.4M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 4
- EPS misses (12Q)
- 6
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +17.0%
- Revenue beats (12Q)
- 7
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $64
- PT range
- $47 – $80
- Analysts
- 3
3 Buy0 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 4, 2026 | -$1.11 | -$1.18 | Miss -6.31% | $490.0K |
| May 7, 2026 | -$0.87 | -$0.91 | Miss -4.60% | $31.7M |
| Feb 24, 2026 | -$1.13 | -$0.10 | Beat 91.15% | $114.1M |
| Nov 4, 2025 | -$0.98 | -$1.10 | Miss -12.24% | $9.7M |
| Feb 27, 2024 | -$1.01 | $1.73 | Beat 271.29% | $316.2M |
| Feb 28, 2023 | -$1.32 | -$0.54 | Beat 59.09% | $20.0M |
| Feb 28, 2022 | -$1.02 | -$0.85 | Beat 16.67% | $51.1M |
| Aug 10, 2021 | -$0.58 | -$0.95 | Miss -63.79% | $6.0K |
| Mar 15, 2021 | -$0.70 | -$0.72 | Miss -2.86% | $6.0K |
| Aug 12, 2020 | -$0.56 | -$0.69 | Miss -23.21% | $6.0K |
| Feb 7, 2020 | — | -$0.54 | — | $6.0K |
| Jun 29, 2019 | — | -$0.51 | — | $6.0K |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 3, 2026